Olanzapine

CHEMBL715 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
312.4 g/mol
LogP
2.9
Phase
4

An atypical antipsychotic balancing dopamine and serotonin activity for schizophrenia, bipolar disorder, and agitation.

분자량

312.4000 g/mol

LogP

2.90

TPSA

59.10 Ų

리핀스키 5의 법칙

통과

치료 영역

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1

InChI

InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

Molecular Formula

C17H20N4S

HBD / HBA

1 / 4

회전 가능 결합

1

무거운 원자

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

An atypical antipsychotic balancing dopamine and serotonin activity for schizophrenia, bipolar disorder, and agitation.

Yes, Olanzapine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL715. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 135398745. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.